Vitamin D2 supplements may negatively impact circulating levels of vitamin D3 and negate the latter's potential benefits, ...

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while ...

The evolution of immunotherapy, featuring CAR-T cells and senolytics, highlights potential in cancer treatment and challenges ...

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell ...

Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned ...

Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The ...

Scale” model spotted a drug combination that made tumors more visible to the immune system, a breakthrough Google calls “a ...

Therapeutics entered into an exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212, a first and potentially ...

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment ...

Amla and turmeric are both Ayurveda-approved food ingredients that are known for their medicinal properties. While they can ...

Researchers from The University of Western Australia have been awarded grants to continue research in childhood diabetes' ...

Google DeepMind's artificial intelligence has discovered a new way to fight cancer. The AI model, Cell2Sentence-Scale 27B, ...